Cladribine

  • Mode of Action and Implications for Treatment of Multiple Sclerosis
  • Thomas P. Leist, Robert Weissert
  • Clinical Neuropharmacology, January 2011, Wolters Kluwer Health
  • DOI: 10.1097/wnf.0b013e318204cd90

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1097/wnf.0b013e318204cd90

The following have contributed to this page: Professor Robert Weissert